Jardiance® improves blood sugar control in type 2 diabetes
A Phase III trial showed Jardiance® is the first SGLT2…
A Phase III trial showed Jardiance® is the first SGLT2 inhibitor to significantly reduce average blood sugar in type 2 diabetics aged 10-17 compared to placebo.